These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 33589532)

  • 1. PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC).
    De Marchi P; Leal LF; Duval da Silva V; da Silva ECA; Cordeiro de Lima VC; Reis RM
    J Clin Pathol; 2021 Nov; 74(11):735-740. PubMed ID: 33589532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 Expression and Tumour Microenvironment Patterns in Resected Non-Small-Cell Lung Cancer.
    Gurevičienė G; Matulionė J; Poškienė L; Miliauskas S; Žemaitis M
    Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541208
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer.
    Jasani B; Bänfer G; Fish R; Waelput W; Sucaet Y; Barker C; Whiteley JL; Walker J; Hovelinck R; Diezko R
    Diagn Pathol; 2020 Apr; 15(1):37. PubMed ID: 32303234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory.
    Vigliar E; Malapelle U; Iaccarino A; Acanfora G; Pisapia P; Clery E; De Luca C; Bellevicine C; Troncone G
    J Clin Pathol; 2019 Jun; 72(6):412-417. PubMed ID: 30846480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed death ligand-1 (PD-L1) clone 22C3 expression in resected colorectal cancer as companion diagnostics for immune checkpoint inhibitor therapy: A comparison study and inter-rater agreement evaluation across proposed cut-offs and predictive (TPS, CPS and IC) scores.
    Lea D; Zaharia C; Søreide K
    Cancer Treat Res Commun; 2024; 38():100788. PubMed ID: 38150845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
    Paver EC; Cooper WA; Colebatch AJ; Ferguson PM; Hill SK; Lum T; Shin JS; O'Toole S; Anderson L; Scolyer RA; Gupta R
    Pathology; 2021 Feb; 53(2):141-156. PubMed ID: 33388161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockade.
    Cortellini A; Zampacorta C; De Tursi M; Grillo LR; Ricciardi S; Bria E; Martini M; Giusti R; Filetti M; Dal Mas A; Russano M; Dall'Olio FG; Buttitta F; Marchetti A
    Pathologica; 2024 Aug; 116(4):222-231. PubMed ID: 39377504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
    Althammer S; Tan TH; Spitzmüller A; Rognoni L; Wiestler T; Herz T; Widmaier M; Rebelatto MC; Kaplon H; Damotte D; Alifano M; Hammond SA; Dieu-Nosjean MC; Ranade K; Schmidt G; Higgs BW; Steele KE
    J Immunother Cancer; 2019 May; 7(1):121. PubMed ID: 31060602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
    Edahiro R; Kanazu M; Kurebe H; Mori M; Fujimoto D; Taniguchi Y; Suzuki H; Hirano K; Yokoyama T; Morita M; Fukuda Y; Uchida J; Makio T; Tamiya M
    PLoS One; 2019; 14(7):e0220570. PubMed ID: 31365588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC.
    Yeong J; Tan T; Chow ZL; Cheng Q; Lee B; Seet A; Lim JX; Lim JCT; Ong CCH; Thike AA; Saraf S; Tan BYC; Poh YC; Yee S; Liu J; Lim E; Iqbal J; Dent R; Tan PH
    J Clin Pathol; 2020 Sep; 73(9):557-562. PubMed ID: 31969377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interobserver agreement in programmed cell death-ligand 1 immunohistochemistry scoring in nonsmall cell lung carcinoma cytologic specimens.
    Sinclair W; Kobalka P; Ren R; Beshai B; Lott Limbach AA; Wei L; Mei P; Li Z
    Diagn Cytopathol; 2021 Feb; 49(2):219-225. PubMed ID: 33104298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interobserver Agreement on the Interpretation of Programmed Death-ligand 1 (PD-L1) Combined Positive Score (CPS) Among Gynecologic Pathologists.
    Mills AM; Bennett JA; Banet N; Watkins JC; Kundu D; Pinto A
    Am J Surg Pathol; 2023 Aug; 47(8):889-896. PubMed ID: 37272261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of a pathologist's personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer.
    Butter R; Hondelink LM; van Elswijk L; Blaauwgeers JLG; Bloemena E; Britstra R; Bulkmans N; van Gulik AL; Monkhorst K; de Rooij MJ; Slavujevic-Letic I; Smit VTHBM; Speel EM; Thunnissen E; von der Thüsen JH; Timens W; van de Vijver MJ; Yick DCY; Zwinderman AH; Cohen D; 't Hart NA; Radonic T
    Lung Cancer; 2022 Apr; 166():143-149. PubMed ID: 35279453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 Assessment in Needle Core Biopsies of Non-Small Cell Lung Cancer: Interpathologist Agreement and Potential Associated Histopathological Features.
    Hacihasanoglu E; Bambul Sigirci B; Usul G; Savli TC
    Turk Patoloji Derg; 2024; 40(1):37-44. PubMed ID: 37614090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer.
    Gagné A; Orain M; Ionescu D; Tsao MS; Joubert D; Joubert P
    Lung Cancer; 2020 Aug; 146():276-284. PubMed ID: 32593917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new AI-assisted scoring system for PD-L1 expression in NSCLC.
    Huang Z; Chen L; Lv L; Fu CC; Jin Y; Zheng Q; Wang B; Ye Q; Fang Q; Li Y
    Comput Methods Programs Biomed; 2022 Jun; 221():106829. PubMed ID: 35660765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Deep Learning-Based Assay for Programmed Death Ligand 1 Immunohistochemistry Scoring in Non-Small Cell Lung Carcinoma: Does it Help Pathologists Score?
    Ito H; Yoshizawa A; Terada K; Nakakura A; Rokutan-Kurata M; Sugimoto T; Nishimura K; Nakajima N; Sumiyoshi S; Hamaji M; Menju T; Date H; Morita S; Bise R; Haga H
    Mod Pathol; 2024 Jun; 37(6):100485. PubMed ID: 38588885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.